Literature DB >> 25979679

Predictive Factors Associated With Acute Ocular Involvement in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Chie Sotozono1, Mayumi Ueta2, Eiji Nakatani3, Amane Kitami4, Hideaki Watanabe4, Hirohiko Sueki4, Masafumi Iijima4, Michiko Aihara5, Zenro Ikezawa5, Yukoh Aihara6, Yoko Kano7, Tetsuo Shiohara7, Mikiko Tohyama8, Yuji Shirakata8, Hideaki Kaneda3, Masanori Fukushima3, Shigeru Kinoshita2, Koji Hashimoto8.   

Abstract

PURPOSE: To suggest an objective score for grading the acute ocular severity of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), and to determine predictive factors for severe acute ocular involvement such as ocular surface epithelial defect and/or pseudomembrane formation.
DESIGN: Retrospective cohort study.
METHODS: The medical records of SJS (n = 87) and TEN (n = 48) patients between 2005 and 2007 were reviewed. An acute ocular severity score was determined on a scale from 0 to 3 (none, mild, severe, and very severe) according to the existence of hyperemia, corneal or conjunctival epithelial defect, and pseudomembrane formation. The associations between the severe acute ocular involvement and factors such as patient age, exposed drugs, systemic severity, and the prevalence of ocular sequelae were examined.
RESULTS: The number of cases with score grade 0, 1, 2, and 3 was 19 (21.8%), 31 (35.6%), 22 (25.3%), and 15 (17.2%) in 87 SJS cases and 12 (25.0%), 11 (22.9%), 17 (35.4%), and 8 (16.7%) in 48 TEN cases. Multivariate logistic regression analysis revealed that patient age (odds ratio [OR], 0.98; 95% confidence interval [CI], 0.96-0.99; P = .007) and nonsteroidal anti-inflammatory drugs NSAIDs or cold remedies (OR, 2.58; 95% CI, 1.26-5.29; P = .010) were predictive factors for severe acute ocular involvement. The prevalence of visual disturbance and eye dryness increased according to the increase of acute ocular severity (P = .001 and P = .007 in SJS; P = .007 and P = .014 in TEN, respectively).
CONCLUSIONS: At the onset of SJS/TEN, strict attention should be paid to ocular involvement in young patients and in patients exposed to NSAIDs or cold remedies.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25979679     DOI: 10.1016/j.ajo.2015.05.002

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  33 in total

1.  [Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis].

Authors:  Argyrios Chronopoulos; Maja Mockenhaupt; Uwe Pleyer
Journal:  Ophthalmologe       Date:  2021-03-16       Impact factor: 1.059

2.  Human Leukocyte Antigen Class I Genes Associated With Stevens-Johnson Syndrome and Severe Ocular Complications Following Use of Cold Medicine in a Brazilian Population.

Authors:  Tais H Wakamatsu; Mayumi Ueta; Katsushi Tokunaga; Yukinori Okada; Renata R Loureiro; Karita A Costa; Juliana Maria F Sallum; José Arthur Milhomens; Chikara Inoue; Chie Sotozono; José Álvaro P Gomes; Shigeru Kinoshita
Journal:  JAMA Ophthalmol       Date:  2017-04-01       Impact factor: 7.389

3.  Long-Term Effect of a Treatment Protocol for Acute Ocular Involvement in Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

Authors:  Swapna S Shanbhag; Ramy Rashad; James Chodosh; Hajirah N Saeed
Journal:  Am J Ophthalmol       Date:  2019-07-19       Impact factor: 5.258

4.  Sutureless amniotic membrane transplantation with cyanoacrylate glue for acute Stevens-Johnson syndrome/toxic epidermal necrolysis.

Authors:  Swapna S Shanbhag; James Chodosh; Hajirah N Saeed
Journal:  Ocul Surf       Date:  2019-03-11       Impact factor: 5.033

Review 5.  Management of Drug-Induced Epidermal Necrolysis (DEN) in Pediatric Patients: Moving from Drug-Induced Stevens-Johnson Syndrome, Overlap and Toxic Epidermal Necrolysis to a Single Unifying Diagnosis of DEN.

Authors:  Michele L Ramien; Danny Mansour; Neil H Shear
Journal:  Paediatr Drugs       Date:  2022-06-09       Impact factor: 3.022

6.  Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome/toxic epidermal necrolysis.

Authors:  Swapna S Shanbhag; Leangelo Hall; James Chodosh; Hajirah N Saeed
Journal:  Ocul Surf       Date:  2020-03-19       Impact factor: 5.033

7.  Clinical Aspects of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis With Severe Ocular Complications in Taiwan.

Authors:  David Hui-Kang Ma; Tsung-Ying Tsai; Li-Yen Pan; Shin-Yi Chen; Ching-Hsi Hsiao; Lung-Kun Yeh; Hsin-Yuan Tan; Chun-Wei Lu; Chun-Bing Chen; Wen-Hung Chung
Journal:  Front Med (Lausanne)       Date:  2021-05-12

Review 8.  Current Perspectives on Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis.

Authors:  Marianne Lerch; Carlo Mainetti; Benedetta Terziroli Beretta-Piccoli; Thomas Harr
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 10.817

9.  Successful Treatment with Chronic Conjunctivitis: Removal of Tarsoconjunctival Crypt.

Authors:  Yun Hyup Na; Se Jung Seo; Joo Youn Shin; Jong Hyun Lee; Jin Hyoung Kim; Do Hyung Lee
Journal:  Korean J Ophthalmol       Date:  2016-07-21

10.  Plasma Lipid Profiling of Patients with Chronic Ocular Complications Caused by Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.

Authors:  Kosuke Saito; Mayumi Ueta; Keiko Maekawa; Chie Sotozono; Shigeru Kinoshita; Yoshiro Saito
Journal:  PLoS One       Date:  2016-11-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.